Global Cell and Gene Therapy Drug Devices Market is Set to Witness Robust Growth at a Steady CAGR of 10.53%, during Forecast Period i.e., 2025-30

• Overview
• Table of Content
• Research Methodology
• Download Free Sample

The Global Cell & Gene Therapy Drug Delivery Devices Market size was valued at around USD 1.27 billion in 2024 and is projected to reach USD 2.32 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 10.53% during the forecast period, i.e., 2025-30, cites MarkNtel Advisors in the recent research report.

The market growth attributes primarily to the rapidly accelerating geriatric population, the increasing prevalence of cancer & chronic disorders, and the surging number of FDA approvals for cell & gene therapies & clinical trials. These therapies not just completely cure chronic conditions but also improve the life quality of patients.

In recent years, the market has gained notable momentum due to the rise in chronic diseases like cancer, diabetes, and rare genetic disorders. The demand for personalized, curative treatments is pushing forward the use of cell and gene therapies, which rely heavily on targeted drug delivery devices to improve efficacy and patient outcomes. This rapidly increasing geriatric population is significantly infusing the need to widen the understanding of the causes behind the numerous genetic & chronic diseases. In turn, it is resulting in the development of modern approaches for their treatment & prevention, further states the research report, “Global Market Analysis, 2025.”

Cell & Gene Therapy Drug Delivery Devices Market Segmentation Analysis

Luxturna Grabbed the Largest Share of the Global Cell & Gene Therapy Drug Delivery Devices Market in Historical Years

Based on the Commercial Drugs segment, the market is further bifurcated into, Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, and Strimvelis.

Among all, Luxturna acquired the largest shares of the market. This flourishing growth is significantly attributed to the growing capabilities to treat children & adult patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy that causes vision loss and might result in complete blindness in certain patients. Luxturna (voretigene neparvovec-rzyl) is the first directly administered gene therapy approved in the US that targets a disease caused by mutations in a specific gene. It works by delivering a copy of the RPE65 gene directly to retinal cells, which produce the normal protein that converts light to an electrical signal in the retina to restore the patient’s vision. It uses a naturally occurring adeno-associated virus (which has been modified using recombinant DNA techniques) as a medium to deliver the normal human RPE65 gene to the retinal cells to restore vision.

North America to Continue Dominating the Global Market Through 2030

In recent years, North America attained majority revenue share of the Global Cell & Gene Therapy Drug Delivery Devices Market, and the same trend is likely to be followed during 2025-30. It owes principally to the increasing focus of conglomerates on collaborating with small & medium enterprises and other distributing channels to develop modern & cost-effective drug delivery devices, intending to expand their global reach and boost the regional market. Moreover, the mounting need to have enhanced treatments for numerous cell & gene diseases through substantial research & diagnostics is another crucial aspect driving the regional market through 2030.

Competitive Landscape

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market players, including Amgen Inc., Bausch & Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio Inc., Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.), Dendreon Pharmaceuticals LLC, Helixmith Co. Ltd (ViroMed Co., Ltd), Human Stem Cells Institute, Kite Pharma Inc., Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer Inc., Renova Therapeutics, Spark Therapeutics Inc., uniQure N.V., Vericel Corporation, and others are looking forward to strengthening their market position.

Key Questions Answered in the Research Report

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the region?
4. How has the industry been evolving in terms of geography & product adoption?
5. How has the competition been shaping across various countries?
6. How has the buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2020-30?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?